HSP90AB1 and non-small cell lung carcinoma: Recent reports of HSP90 inhibitor activity in human non-small cell lung cancer (NSCLC) phase IIb/III clinical trials have provided compelling rationale for investigating the feasibility of using HSP90 inhibitors for treatment of lung cancer in dogs [24].